Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 57 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Desvenlafaxine Succinate Clear all
Not listed No phase listed Observational

Tracking Response to Antidepressants in Advance of Investigational Trials

NCT04748276
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Drug
Lead sponsor
Adams Clinical
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

NCT01537068
View directory record Official record
Conditions
Dysthymic Disorder, Dysthymia, Chronic Depressive Disorder
Interventions
Desvenlafaxine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

NCT00619619
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

NCT03357796
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects

NCT00329186
View directory record Official record
Conditions
Healthy
Interventions
desvenlafaxine SR, venlafaxine ER
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 2Phase 3 Interventional Results available

TRIAD - Treatment of Insomnia and Depression

NCT00767624
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Antidepressant, Desensitization Therapy for Insomnia, Cognitive Behavioral Therapy for Insomnia
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Stanford, California • Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

NCT02400346
View directory record Official record
Conditions
Major Depression Disorder
Interventions
Adjunct brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
65 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Arcadia, California • Miami, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

NCT00887224
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine succinate sustained release 50 mg, Desvenlafaxine succinate sustained release 25 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Beverly Hills, California • Encino, California • Los Alamitos, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Food Effect Study of LY03005

NCT03822065
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Peoria, Arizona • Pasadena, California • San Diego, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01371734
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Imperial, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

NCT01121484
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained-release, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arcadia, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

NCT01371721
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
33
States / cities
Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam

NCT00952653
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained Release, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

NCT00440427
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Desvenlafaxine Sustained Release (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

NCT01188668
View directory record Official record
Conditions
Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
Interventions
Aripiprazole, Aripiprazole + desvenlafaxine succinate sustained release
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY03005 vs Pristiq

NCT03733574
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 1, 2026, 2:08 PM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy

NCT00283842
View directory record Official record
Conditions
Diabetic Neuropathies, Pain
Interventions
DVS SR, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
51
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

NCT01371708
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • Imperial, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

NCT01309542
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
53
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 1, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

NCT01469377
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Garden Grove, California • National City, California • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 1, 2026, 2:08 PM EDT